Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Ie D, Yannuzzi LA, Spaide RF, Rabb MF, Blair NP, Daily MJ . Subretinal exudative deposits in central serous chorioretinopathy. Br J Ophthalmol 1993; 77: 349–353.
Iida T, Spaide RF, Haas A, Yannuzzi LA, Jampol LM, Lesser RL . Leopard-spot pattern of yellowish subretinal deposits in central serous chorioretinopathy. Arch Ophthalmol 2002; 120: 37–42.
Iida T, Yannuzzi LA, Spaide RF, Borodoker N, Carvalho CA, Negrao S . Cystoid macular degeneration in chronic central serous chorioretinopathy. Retina 2003; 23: 1–7.
Wang M, Munch IC, Hasler PW, Prünte C, Larsen M . Central serous chorioretinopathy. Acta Ophthalmol Scand 2008; 86: 126–145.
Yannuzzi LA, Slakter JS, Kaufman SR, Gupta K . Laser treatment of diffuse retinal pigment epitheliopathy. Eur J Ophthalmol 1992; 2: 103–114.
Ober MD, Yannuzzi LA, Do DV, Spaide RF, Bressler NM, Jampol LM et al. Photodynamic therapy for focal retinal pigment epithelial leaks secondary to central serous chorioretinopathy. Ophthalmology 2005; 112: 2088–2094.
Cardillo Piccolino F, Eandi CM, Ventre L, Rigault de la Longrais RC, Grignolo FM . Photodynamic therapy for chronic central serous chorioretinopathy. Retina 2003; 23: 752–763.
Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO . Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003; 22: 1–29.
Author information
Authors and Affiliations
Additional information
The authors have no proprietary or financial interest in any material or device mentioned
Rights and permissions
About this article
Cite this article
Huang, WC., Chen, WL., Tsai, YY. et al. Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy. Eye 23, 488–489 (2009). https://doi.org/10.1038/eye.2008.55
Published:
Issue date:
DOI: https://doi.org/10.1038/eye.2008.55
This article is cited by
-
Clinical characteristics of responders to intravitreal bevacizumab in central serous chorioretinopathy patients
Eye (2015)
-
Efficacy of half-fluence photodynamic therapy depending on the degree of choroidal hyperpermeability in chronic central serous chorioretinopathy
Eye (2013)
-
Short-term efficacy of intravitreal dobesilate in central serous chorioretinopathy
European Journal of Medical Research (2012)
-
Intravitreal bevacizumab versus low-fluence photodynamic therapy for treatment of chronic central serous chorioretinopathy
Japanese Journal of Ophthalmology (2012)
-
Alterations in “in vivo” histology of retina in bilateral chronic central serous chorioretinopathy after intravitreal bevacizumab
Journal of Ocular Biology, Diseases, and Informatics (2011)
